These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1491 related articles for article (PubMed ID: 25773268)

  • 1. Long-term use of ticagrelor in patients with prior myocardial infarction.
    Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Jensen EC; Magnani G; Bansilal S; Fish MP; Im K; Bengtsson O; Oude Ophuis T; Budaj A; Theroux P; Ruda M; Hamm C; Goto S; Spinar J; Nicolau JC; Kiss RG; Murphy SA; Wiviott SD; Held P; Braunwald E; Sabatine MS;
    N Engl J Med; 2015 May; 372(19):1791-800. PubMed ID: 25773268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
    Dellborg M; Bonaca MP; Storey RF; Steg PG; Im KA; Cohen M; Bhatt DL; Oude Ophuis T; Budaj A; Hamm C; Spinar J; Kiss RG; Lopez-Sendon J; Kamensky G; Van de Werf F; Ardissino D; Kontny F; Montalescot G; Johanson P; Bengtsson O; Himmelmann A; Braunwald E; Sabatine MS
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):200-206. PubMed ID: 31218354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
    Bhatt DL; Bonaca MP; Bansilal S; Angiolillo DJ; Cohen M; Storey RF; Im K; Murphy SA; Held P; Braunwald E; Sabatine MS; Steg PG
    J Am Coll Cardiol; 2016 Jun; 67(23):2732-2740. PubMed ID: 27046160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
    Bonaca MP; Bhatt DL; Steg PG; Storey RF; Cohen M; Im K; Oude Ophuis T; Budaj A; Goto S; López-Sendón J; Diaz R; Dalby A; Van de Werf F; Ardissino D; Montalescot G; Aylward P; Magnani G; Jensen EC; Held P; Braunwald E; Sabatine MS
    Eur Heart J; 2016 Apr; 37(14):1133-42. PubMed ID: 26491109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
    Magnuson EA; Li H; Wang K; Vilain K; Shafiq A; Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Braunwald E; Sabatine MS; Cohen DJ;
    J Am Coll Cardiol; 2017 Aug; 70(5):527-538. PubMed ID: 28750695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
    N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
    Bonaca MP; Bhatt DL; Braunwald E; Cohen M; Steg PG; Storey RF; Held P; Jensen EC; Sabatine MS
    Am Heart J; 2014 Apr; 167(4):437-444.e5. PubMed ID: 24655690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
    Bonaca MP; Bhatt DL; Oude Ophuis T; Steg PG; Storey R; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Theroux P; Hamm C; Špinar J; Kiss RG; Dalby AJ; Medina FA; Kontny F; Aylward PE; Jensen EC; Held P; Braunwald E; Sabatine MS
    JAMA Cardiol; 2016 Jul; 1(4):425-32. PubMed ID: 27438319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
    Magnani G; Storey RF; Steg G; Bhatt DL; Cohen M; Kuder J; Im K; Aylward P; Ardissino D; Isaza D; Parkhomenko A; Goudev AR; Dellborg M; Kontny F; Corbalan R; Medina F; Jensen EC; Held P; Braunwald E; Sabatine MS; Bonaca MP
    Eur Heart J; 2016 Jan; 37(4):400-8. PubMed ID: 26443023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
    Johnston SC; Amarenco P; Albers GW; Denison H; Easton JD; Evans SR; Held P; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KS;
    N Engl J Med; 2016 Jul; 375(1):35-43. PubMed ID: 27160892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
    Bonaca MP; Storey RF; Theroux P; Steg PG; Bhatt DL; Cohen MC; Im K; Murphy SA; Magnani G; Ophuis TO; Rudah M; Parkhomenko A; Isaza D; Kamensky G; Goudev A; Montalescot G; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2017 Sep; 70(11):1368-1375. PubMed ID: 28882235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
    BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.
    Bergmark BA; Bhatt DL; Steg PG; Budaj A; Storey RF; Gurmu Y; Kuder JF; Im K; Magnani G; Oude Ophuis T; Hamm C; Špinar J; Kiss RG; Van de Werf FJ; Montalescot G; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
    J Am Heart Assoc; 2021 Sep; 10(17):e020446. PubMed ID: 34423649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.
    Al-Salama ZT; Keating GM; Keam SJ
    Drugs; 2017 Dec; 77(18):2025-2036. PubMed ID: 29150806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
    Magnani G; Ardissino D; Im K; Budaj A; Storey RF; Steg PG; Bhatt DL; Cohen M; Oude Ophius T; Goudev A; Parkhomenko A; Kamensky G; Angiolillo DJ; López-Sendón J; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
    J Am Heart Assoc; 2021 Feb; 10(4):e017008. PubMed ID: 33559485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.